These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 37022569)

  • 41.
    Quelven I; Monteil J; Sage M; Saidi A; Mounier J; Bayout A; Garrier J; Cogne M; Durand-Panteix S
    J Nucl Med; 2020 Jul; 61(7):1058-1065. PubMed ID: 31862796
    [TBL] [Abstract][Full Text] [Related]  

  • 42. CD38-specific nanobodies allow
    Pape LJ; Hambach J; Gebhardt AJ; Rissiek B; Stähler T; Tode N; Khan C; Weisel K; Adam G; Koch-Nolte F; Bannas P
    Front Immunol; 2022; 13():1010270. PubMed ID: 36389758
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Daratumumab: monoclonal antibody therapy to treat multiple myeloma.
    Xia C; Ribeiro M; Scott S; Lonial S
    Drugs Today (Barc); 2016 Oct; 52(10):551-560. PubMed ID: 27910963
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Targeting of CD38 by the Tumor Suppressor miR-26a Serves as a Novel Potential Therapeutic Agent in Multiple Myeloma.
    Hu Y; Liu H; Fang C; Li C; Xhyliu F; Dysert H; Bodo J; Habermehl G; Russell BE; Li W; Chappell M; Jiang X; Ondrejka SL; Hsi ED; Maciejewski JP; Yi Q; Anderson KC; Munshi NC; Ao G; Valent JN; Lin J; Zhao J
    Cancer Res; 2020 May; 80(10):2031-2044. PubMed ID: 32193289
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Daratumumab monotherapy compared with historical control data in heavily pretreated and highly refractory patients with multiple myeloma: An adjusted treatment comparison.
    Usmani SZ; Diels J; Ito T; Mehra M; Khan I; Lam A
    Am J Hematol; 2017 Aug; 92(8):E146-E152. PubMed ID: 28474745
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.
    de Weers M; Tai YT; van der Veer MS; Bakker JM; Vink T; Jacobs DC; Oomen LA; Peipp M; Valerius T; Slootstra JW; Mutis T; Bleeker WK; Anderson KC; Lokhorst HM; van de Winkel JG; Parren PW
    J Immunol; 2011 Feb; 186(3):1840-8. PubMed ID: 21187443
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Daratumumab in multiple myeloma.
    Nooka AK; Kaufman JL; Hofmeister CC; Joseph NS; Heffner TL; Gupta VA; Sullivan HC; Neish AS; Dhodapkar MV; Lonial S
    Cancer; 2019 Jul; 125(14):2364-2382. PubMed ID: 30951198
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO).
    San-Miguel J; Usmani SZ; Mateos MV; van de Donk NWCJ; Kaufman JL; Moreau P; Oriol A; Plesner T; Benboubker L; Liu K; Hellemans P; Masterson T; Clemens PL; Luo M; Farnsworth A; Nahi H; Chari A
    Haematologica; 2021 Jun; 106(6):1725-1732. PubMed ID: 32354874
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Daratumumab in multiple myeloma: experience of the multiple myeloma GIMEMA Lazio group.
    Vozella F; Siniscalchi A; Rizzo M; Za T; Antolino G; Coppetelli U; Piciocchi A; Andriani A; Annibali O; De Rosa L; Cimino G; La Verde G; De Stefano V; Cantonetti M; di Toritto TC; Petrucci MT
    Ann Hematol; 2021 Apr; 100(4):1059-1063. PubMed ID: 33528611
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Monoclonal Antibodies in Multiple Myeloma: A New Wave of the Future.
    Sherbenou DW; Mark TM; Forsberg P
    Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):545-554. PubMed ID: 28734795
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma.
    Sanchez L; Richter J; Cho HJ; Jagannath S; Madduri D; Parekh S; Richard S; Tam L; Verina D; Chari A
    Ther Adv Hematol; 2021; 12():2040620720987075. PubMed ID: 33613930
    [TBL] [Abstract][Full Text] [Related]  

  • 52. 'Fast but not so Furious': Short observation time after subcutaneous Daratumumab administration is both a safe and cost-effective strategy.
    Davis JA; Youngberg H; Gaffney K; Duco M; Hashmi H
    Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):e680-e684. PubMed ID: 35414476
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma.
    Casneuf T; Xu XS; Adams HC; Axel AE; Chiu C; Khan I; Ahmadi T; Yan X; Lonial S; Plesner T; Lokhorst HM; van de Donk NWCJ; Clemens PL; Sasser AK
    Blood Adv; 2017 Oct; 1(23):2105-2114. PubMed ID: 29296857
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma.
    Moreau P; van de Donk NW; San Miguel J; Lokhorst H; Nahi H; Ben-Yehuda D; Cavo M; Cook G; Delforge M; Einsele H; Zweegman S; Ludwig H; Driessen C; Palumbo A; Facon T; Plesner T; Dimopoulos M; Sondergeld P; Sonneveld P; Mateos MV
    Drugs; 2016 May; 76(8):853-67. PubMed ID: 27113582
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma.
    Sanchez L; Wang Y; Siegel DS; Wang ML
    J Hematol Oncol; 2016 Jun; 9(1):51. PubMed ID: 27363983
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Deep sustained response to daratumumab monotherapy associated with T-cell expansion in triple refractory myeloma.
    Usmani SZ; Khan I; Chiu C; Foureau D; Druhan LJ; Rigby K; Casneuf T; Sasser AK
    Exp Hematol Oncol; 2018; 7():3. PubMed ID: 29445583
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Daratumumab - Hope for Myeloma Patients, a Challenge for Clinical Laboratories].
    Jelínek T; Kořístka M; Čermáková Z; Hájek R
    Klin Onkol; 2017; 30(1):13-19. PubMed ID: 28185460
    [TBL] [Abstract][Full Text] [Related]  

  • 58. CD38-negative relapse in multiple myeloma after daratumumab-based chemotherapy.
    Minarik J; Novak M; Flodr P; Balcarkova J; Mlynarcikova M; Krhovska P; Pika T; Pikalova Z; Bacovsky J; Scudla V
    Eur J Haematol; 2017 Aug; 99(2):186-189. PubMed ID: 28470777
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma.
    Zhang T; Wang S; Lin T; Xie J; Zhao L; Liang Z; Li Y; Jiang J
    Oncotarget; 2017 May; 8(20):34001-34017. PubMed ID: 28454113
    [TBL] [Abstract][Full Text] [Related]  

  • 60. CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience.
    Frerichs KA; Nagy NA; Lindenbergh PL; Bosman P; Marin Soto J; Broekmans M; Groen RWJ; Themeli M; Nieuwenhuis L; Stege C; Nijhof IS; Mutis T; Zweegman S; Lokhorst HM; van de Donk NWCJ
    Expert Rev Clin Immunol; 2018 Mar; 14(3):197-206. PubMed ID: 29465271
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.